BACKGROUND: Diabetes mellitus is a risk for increased incidence of adverse clinical events after percutaneous coronary intervention. However, the difference in the incidence of adverse clinical events according to stent type in patients with diabetes remains to be elucidated. In the present study, we aimed to compare the clinical outcomes between patients treated with the biodegradable polymer sirolimus-eluting stents (BP-SES) and the durable polymer everolimus-eluting stents (DP-EES) among patients with diabetes. METHODS: Among 631 lesions in 510 consecutive patients treated with either BP-SES or DP-EES, 165 lesions in 141 patients with diabetes mellitus and stable angina pectoris were identified and classified into the BP-SES group (48 lesions in 44 patients) and the DP-EES group (117 lesions in 100 patients). The incidence of adverse clinical events after stent implantation was compared between the 2 groups. RESULTS: There was no significant difference in the prevalence of conventional risk factors, lesion characteristics, and procedural characteristics between the 2 groups. During median 386 [334-472] days follow-up, the incidence of target lesion revascularization (11.4 vs. 2.0%, p = 0.003) and device-oriented clinical endpoint (13.6 vs. 6.0%, p = 0.035) in the BP-SES group was significantly greater than that in the DP-EES group. A univariate model demonstrated that the BP-SES usage was significantly associated with the higher incidence of target lesion revascularization (odds ratio, 6.686; 95% confidence interval, 1.234-36.217; p = 0.028). CONCLUSION: BP-SES was associated with the greater incidence of TLR than the DP-EES in patients with diabetes mellitus. Further studies with larger cohorts and longer follow-up are required to confirm the present results.
BACKGROUND:Diabetes mellitus is a risk for increased incidence of adverse clinical events after percutaneous coronary intervention. However, the difference in the incidence of adverse clinical events according to stent type in patients with diabetes remains to be elucidated. In the present study, we aimed to compare the clinical outcomes between patients treated with the biodegradable polymersirolimus-eluting stents (BP-SES) and the durable polymereverolimus-eluting stents (DP-EES) among patients with diabetes. METHODS: Among 631 lesions in 510 consecutive patients treated with either BP-SES or DP-EES, 165 lesions in 141 patients with diabetes mellitus and stable angina pectoris were identified and classified into the BP-SES group (48 lesions in 44 patients) and the DP-EES group (117 lesions in 100 patients). The incidence of adverse clinical events after stent implantation was compared between the 2 groups. RESULTS: There was no significant difference in the prevalence of conventional risk factors, lesion characteristics, and procedural characteristics between the 2 groups. During median 386 [334-472] days follow-up, the incidence of target lesion revascularization (11.4 vs. 2.0%, p = 0.003) and device-oriented clinical endpoint (13.6 vs. 6.0%, p = 0.035) in the BP-SES group was significantly greater than that in the DP-EES group. A univariate model demonstrated that the BP-SES usage was significantly associated with the higher incidence of target lesion revascularization (odds ratio, 6.686; 95% confidence interval, 1.234-36.217; p = 0.028). CONCLUSION:BP-SES was associated with the greater incidence of TLR than the DP-EES in patients with diabetes mellitus. Further studies with larger cohorts and longer follow-up are required to confirm the present results.
Authors: Ron Waksman; Evan Shlofmitz; Stephan Windecker; Jacques J Koolen; Shigeru Saito; David Kandzari; Paul Kolm; Michael J Lipinski; Rebecca Torguson Journal: Am J Cardiol Date: 2019-07-15 Impact factor: 2.778
Authors: Lisette Okkels Jensen; Michael Maeng; Bent Raungaard; Johnny Kahlert; Julia Ellert; Lars Jakobsen; Anton Boel Villadsen; Karsten Tange Veien; Steen Dalby Kristensen; Ole Ahlehoff; Steen Carstensen; Martin Kirk Christensen; Christian Juhl Terkelsen; Thomas Engstroem; Knud Nørregaard Hansen; Hans Erik Bøtker; Jens Aaroe; Troels Thim; Leif Thuesen; Philip Freeman; Ahmed Aziz; Ashkan Eftekhari; Anders Junker; Svend Eggert Jensen; Jens Flensted Lassen; Henrik Steen Hansen; Evald Høj Christiansen Journal: Circulation Date: 2020-05-21 Impact factor: 29.690
Authors: Bo Lagerqvist; Stefan K James; Ulf Stenestrand; Johan Lindbäck; Tage Nilsson; Lars Wallentin Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Pawel Gasior; Marek Gierlotka; Krzysztof Szczurek-Katanski; Marcin Osuch; Magda Roleder; Michał Hawranek; Wojciech Wojakowski; Lech Polonski Journal: Cardiol J Date: 2020-01-07 Impact factor: 2.737
Authors: Juan F Iglesias; Dik Heg; Marco Roffi; David Tüller; Jonas Lanz; Fabio Rigamonti; Olivier Muller; Igal Moarof; Stéphane Cook; Daniel Weilenmann; Christoph Kaiser; Florim Cuculi; Marco Valgimigli; Peter Jüni; Stephan Windecker; Thomas Pilgrim Journal: J Am Heart Assoc Date: 2019-11-07 Impact factor: 5.501